PMID- 35240677
OWN - NLM
STAT- MEDLINE
DCOM- 20220509
LR  - 20230315
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
VI  - 139
IP  - 18
DP  - 2022 May 5
TI  - CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?
PG  - 2737-2746
LID - 10.1182/blood.2022015789 [doi]
AB  - The standard of care treatment strategy for patients with relapsed or refractory 
      large B-cell lymphoma (LBCL) has been high-dose chemotherapy followed by 
      autologous stem cell transplantation (ASCT) if chemotherapy sensitive in suitable 
      patients. Because of treatment intensity, this approach has only been feasible in 
      half of patients and because of chemotherapy resistance has only been successful 
      in a quarter of transplant-eligible patients. Chimeric antigen receptor (CAR) 
      T-cell therapy, using genetically modified autologous T cells targeting CD19, has 
      been approved for third-line therapy of LBCL and has been associated with durable 
      remissions in a proportion of patients. In this review, we interpret the design 
      and results of 3 randomized phase 3 trials comparing CAR T-cell therapy and ASCT 
      and their implications for CAR T-cell therapy as a potential new standard of care 
      for second-line treatment in appropriate patients with refractory or early 
      relapsing LBCL.
CI  - (c) 2022 by The American Society of Hematology.
FAU - Westin, Jason
AU  - Westin J
AUID- ORCID: 0000-0002-1824-2337
AD  - Division of Cancer Medicine, Department of Lymphoma and Myeloma, University of 
      Texas MD Anderson Cancer Center, Houston, TX; and.
FAU - Sehn, Laurie H
AU  - Sehn LH
AUID- ORCID: 0000-0003-1860-9765
AD  - BC Cancer Centre for Lymphoid Cancer and the University of British Columbia, 
      Vancouver, BC, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Antigens, CD19)
RN  - 0 (Receptors, Chimeric Antigen)
SB  - IM
EIN - Blood. 2023 Feb 9;141(6):683. PMID: 36757722
MH  - Antigens, CD19
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Immunotherapy, Adoptive/methods
MH  - *Lymphoma, Large B-Cell, Diffuse/pathology
MH  - *Receptors, Chimeric Antigen/therapeutic use
MH  - T-Lymphocytes
MH  - Transplantation, Autologous
EDAT- 2022/03/04 06:00
MHDA- 2022/05/10 06:00
CRDT- 2022/03/03 20:21
PHST- 2022/02/02 00:00 [received]
PHST- 2022/03/02 00:00 [accepted]
PHST- 2022/03/04 06:00 [pubmed]
PHST- 2022/05/10 06:00 [medline]
PHST- 2022/03/03 20:21 [entrez]
AID - S0006-4971(22)00319-6 [pii]
AID - 10.1182/blood.2022015789 [doi]
PST - ppublish
SO  - Blood. 2022 May 5;139(18):2737-2746. doi: 10.1182/blood.2022015789.